88475-69-8

Beraprost sodium is a new, orally active antithrombotic epoprostenol analog introduced as a treatment for peripheral vascular disease, including Raynaud's syndrome and Buerger's disease. The antiplatelet activity may be due to its elevation of cyclic AMP in platelets which is achieved by activating adenylate cyclase in the platelet membrane, followed by the inhibition ofCa⁺⁺- influx and thromboxane A2 formation.

White Solid

Toray (Japan)

Platelet aggregation inhibitor; stable analog of Prostacyclin. Antithrombotic; vasodilator (peripheral).

ChEBI: Beraprost sodium is the organic sodium salt of beraprost. It is used in the treatment of chronic arterial occlusive disease and primary pulmonary hypertension in Japan. It has a role as an antihypertensive agent, a platelet aggregation inhibitor, a prostaglandin receptor agonist, a vasodilator agent and an anti-inflammatory agent. It contains a beraprost(1-).

Dorner; Dorner;Procylin

Beraprost sodium is used as a therapeutic agent for chronic artery obstructions or primary pulmonary hypertension. In individuals with coronary artery disease, beraprost sodium helps to reduce oxidative stress and developed forearm endothelium dependent vasodilation.

Disease-related events had similar incidence in patients receiving beraprost and those receiving placebo. Drug-related adverse events like headache, flushing, jaw pain, and diarrhea were more common in patients treated with beraprost sodium and occurred mostly during the six-week titration period. The incidence was markedly reduced in the maintenance period. Six patients (9%) in the beraprost sodium group and two (3%) in the placebo group withdrew prematurely from the study because of adverse events. No clinically adverse changes in hematologic or biochemical variables were seen in the beraprost sodium group.

[1] NORITOSHI NAGAYA MD  Masaaki U M, PHD  Toru S M  Yoshiaki Okano MD, PHD  Shingo K M, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension[J]. Journal of the American College of Cardiology, 1999, 34 4: Pages 1188-1192. DOI: 10.1016/s0735-1097(99)00312-5
[2] P. NONY. Platelet-aggregation inhibition and hemodynamic effects of beraprost sodium, a new oral prostacyclin derivative: a study in healthy male subjects.[J]. Canadian journal of physiology and pharmacology, 1996, 74 8 1: 887-893. DOI: 10.1139/y96-088
[3] H KATO. Effect of beraprost sodium, a stable prostaglandin I2 analogue, on platelet aggregation in diabetes mellitus.[J]. International journal of clinical pharmacology research, 1996, 16 4-5: 99-102.
[4] SHAFIQUE AHMAD. Ameliorative Effect of Beraprost Sodium on Celecoxib Induced Cardiotoxicity in Rats.[J]. Iranian Journal of Pharmaceutical Research, 2018, 17 1: 155-163.